Looking at where the field stands today, what kind of excites you the most about this area? You know, where do you see maybe the the next frontier in IBD, but also maybe just in immunology in general.

In IBD in particular, but also across other autoimmune diseases, the majority of them, they're quite heterogeneous.

So multiple pathways, different kinds of baseline biology that drive disease.

And what we've seen since the advent of advanced treatments, so infliximab, Humira, almost 20, 25 years of access to these treatments is You know, we've seen a plateauing of effect.

So we've been able to make these incremental improvements over the years.

So when I started at AbbVie, we had Humira.

And then we developed Skyrizzy and Renvoke and IBD.

Yeah, are there other insights like you mentioned that you wanted to touch on more broadly across AbbVie and some of the other autoimmune projects you guys are working on?